Form D · Biotechnology
Immunitas Therapeutics, Inc.
Waltham, MA · CIK 0001879910
Offering snapshot reported Aug 24, 2021 · SEC filing
- Reported sold
- $29.1M Offering amount: $57.7M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 10, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 24, 2021 | Initial | $29,080,112 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-411076
Source: Form D, filed Aug 24, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Laura Brass | Director |
| Juergen Eckhardt | Director |
| Jeffrey Goldberg | Director, Executive |
| Jiaping Gu | Director |
| Lucio Iannone | Director |
| Dan Matloff | Executive |
| Amanda Wagner | Executive |
| Christoph Westphal | Director |
| Kai Wucherpfennig | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
830 Winter Street, 2 Nd Floor
Waltham, MA, 02451
Waltham, MA, 02451